SRTOY (Sartorius Stedim Biotech) Scaled Net Operating Assets: 0.77 (As of Mar. 2026)


SRTOY Sartorius Stedim Biotech SA SRTOY
82 GF Score
Price $20.11
GF Value $23.65
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sartorius Stedim Biotech Scaled Net Operating Assets?

Sartorius Stedim Biotech SRTOY +0.10% 82 Scaled Net Operating Assets is 0.77 as of Mar. 2026. GuruFocus rates SRTOY with a GF Score™ of 82/100 and a GF Value™ of $23.65 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sartorius Stedim Biotech's operating assets for the quarter that ended in Mar. 2026 was $8,835 Mil. Sartorius Stedim Biotech's operating liabilities for the quarter that ended in Mar. 2026 was $1,656 Mil. Sartorius Stedim Biotech's Total Assets for the quarter that ended in Dec. 2025 was $9,349 Mil. Therefore, Sartorius Stedim Biotech's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.77.


Sartorius Stedim Biotech Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Sartorius Stedim Biotech's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius Stedim Biotech Scaled Net Operating Assets Chart

Sartorius Stedim Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.69 0.84 1.27 0.77 0.85

Sartorius Stedim Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.78 0.81 0.77 0.80 0.77

SRTOY vs ISRG, BDX, MDLN: Scaled Net Operating Assets Comparison

For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sartorius Stedim Biotech Scaled Net Operating Assets vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Sartorius Stedim Biotech's Scaled Net Operating Assets falls into.


SRTOY
82GF Score
Sartorius Stedim Biotech SA SRTOY
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sartorius Stedim Biotech Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sartorius Stedim Biotech's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(8840.515-1473.77)/8645.445
=0.85

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=9348.946 - 508.431
=8840.515

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=4517.447 - 2363.7 - 679.977
=1473.77

Sartorius Stedim Biotech's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(8835.145-1655.723)/9348.946
=0.77

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=9467.977 - 632.832
=8835.145

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=4678.382 - 2322.428 - 700.231
=1655.723

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.77 mean?
Sartorius Stedim Biotech (SRTOY) has a Scaled Net Operating Assets of 0.77 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Sartorius Stedim Biotech and its competitors.
Is Sartorius Stedim Biotech's Scaled Net Operating Assets too high?
Sartorius Stedim Biotech's current Scaled Net Operating Assets is 0.77. Overall, Sartorius Stedim Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Scaled Net Operating Assets compare to ISRG and BDX?
Sartorius Stedim Biotech's Scaled Net Operating Assets of 0.77 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Sartorius Stedim Biotech and its competitors. Sartorius Stedim Biotech's current Scaled Net Operating Assets is 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (SRTOY) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.65, compared to a current price of $20.11 — trading 15% below its estimated fair value. The current Scaled Net Operating Assets is 0.77. Sartorius Stedim Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Sartorius Stedim Biotech (SRTOY), the current Scaled Net Operating Assets is 0.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius Stedim Biotech (SRTOY) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of $20.11 is trading 15% below its estimated GF Value™ of $23.65. GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.

Key valuation signals for SRTOY:

  • Scaled Net Operating Assets: 0.77
  • GF Value™: $23.65 vs. price of $20.11 (15% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the SRTOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sartorius Stedim Biotech Business Description

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score

Get the complete analysis for SRTOY

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.11
Price
$23.65
GF Value